Navigation Links
Prismic Pharmaceuticals Acquires Scarista's Exclusive License to Amarin's Omega-3 Patents for CNS Disorders
Date:2/7/2012

SCOTTSDALE, Ariz., Feb. 7, 2012 /PRNewswire/ -- Prismic Pharmaceuticals, Inc., a Scottsdale, Arizona-based, emerging pharmaceutical company, today announced that it has completed the acquisition of the assets of Scarista Limited. In particular, Prismic has acquired Scarista's exclusive license from Amarin Neuroscience Limited, a wholly owned subsidiary of Amarin Corporation, to develop, market, and out-license products based on a portfolio of issued U.S. and foreign composition and use patents covering highly purified forms of Omega-3 fatty acids alone or in combination with other molecules for the treatment of disorders of the central nervous system (CNS). 

Commenting on this acquisition, Peter Moriarty, the Chairman and co-founder of the company, stated, "This is an important milestone in the development of Prismic Pharmaceuticals. Having gained access to the robust patents through the acquisition of Scarista, Prismic is planning to partner with one or more pharmaceutical companies in order to maximize the considerable commercial opportunity the patents offer in the CNS area."  

"There is already an established body of research and clinical experience indicating the therapeutic benefits and safety of highly purified forms of EPA and DHA for the treatment of cardiovascular disease. There is also similar data relating to their use in the treatment of a number of CNS disorders," Moriarty added. "Prismic, therefore, believes that any company licensing our IP will have the opportunity to bring patent-protected formulations to market relatively expeditiously." 

About Prismic Pharmaceuticals, Inc.

Prismic Pharmaceuticals, Inc., is a privately held pharmaceutical company focused on the development and marketing of novel prescription pharmaceuticals for psychiatric and neurodegenerative disorders, and prescription medical foods for the clinical dietary management of the metabolic processes associate
'/>"/>

SOURCE Prismic Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , BOCA RATON, Fla., Nov. 18 Lexington Intl, manufacturer ... 14 leading manufacturing exporting companies nationwide to receive the President,s ... contributions to the U.S. economy. , Presented to Lexington at ... U.S. Secretary of Commerce, Gary Locke and Florida Senator George ...
... Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ) has ... approval from the US Food and Drug Administration (FDA). ... of hypertension when oral therapy is not feasible or ... 25 mg/10ml single use ampuls containing 2.5 mg/ml of ...
Cached Medicine Technology:Lexington International, LLC Receives 2009 U.S. President's 'E' Award Recognizing its Export Achievements 2Lexington International, LLC Receives 2009 U.S. President's 'E' Award Recognizing its Export Achievements 3Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection 2
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... (Providence, RI)--- EpiVax, Inc, a leader in the field ... funding from the Juvenile Diabetes Research Foundation (JDRF), the ... to develop Epi-13, a novel therapeutic for the prevention ... chronic autoimmune disease that affects up to three million ...
... 2007 - Diseases that cause neurons to break-down, ... (Mad Cow Disease), continue to be elusive to ... from University of Michigan researchers demonstrates an unpredicted ... neuron health., In a study released in PNAS, ...
... ElBaradei will join more than 100 leading public figures, ... in New York on 29 October to mark the ... the US based National Foundation for Cancer Research (NFCR). ... PACT Fund at NFCR, Americans can support the IAEA ...
... is generally considered to be safe with a low ... tube can lead to serious complications. , The ... Dr. Imamura of Aichi Medical University Hospital. It was ... Gastroenterology. , An 86-year-old woman with gastrostomy tube feeding ...
... ALTO, Calif., Oct. 25 ASTRO Booth # ... today announced that it has developed,groundbreaking technology for ... of volumetric arc therapy. Varian,s new RapidArc(TM),radiotherapy technology* ... to deliver more precise forms of intensity-modulated radiation,therapy ...
... Coley,Pharmaceutical Group, Inc. (Nasdaq: COLY ), today announced ... 4:30 p.m. Eastern Time on November,1, 2007 to discuss ... live audio broadcast or the subsequent archived recording,of the ... Coley website,at http://www.coleypharma.com . Please log onto Coley,s ...
Cached Medicine News:Health News:EpiVax receives JDRF program funding to develop diabetes drug using natural 'regulatory' T-cells 2Health News:U-M scientists find new causes for neurodegeneration 2Health News:IAEA and NFCR join forces to fight cancer in developing world 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 2Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 3Health News:Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007 4Health News:Coley Pharmaceutical Group to Report Third Quarter Results on November 1, 2007 2
... Card is specially designed to be a corrected ... Rosenbaum card (as noted by Horton and Jones ... "J" notations are not used because of the ... the Wormington NP Card, the examiner can measure ...
Standard reading test. 'It was the month of May'...
Standard reading test. "Children should be..."...
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
Medicine Products: